Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 20.01M shares outstanding
USNeurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions.
Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease).
The company's operations are based in New York, New York.
Christine Mikail Cvijic, J.D.
President and Chief Financial Officer
Julie Jordan, M.D.
Chief Medical Officer
Rachel McMinn, Ph.D.
Executive Chair and Chief Executive Officer
Rachel McMinn, Ph.D.(1)
Executive Chair and Chief Executive Officer
Employees
131
Country
US
Sector
Healthcare
Website
neurogene.com
Loading congressional disclosures…
based on 20.01M shares outstanding
US30d Avg
352.76K
60d Avg
280.50K
90d Avg
250.12K
